Evidence map›Paper›PMID 33952785›Full record

ReviewMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2022

State-of-the-art MR Imaging for Thoracic Diseases.

Yumi Tanaka, Yoshiharu Ohno, Satomu Hanamatsu, Yuki Obama, Takahiro Ueda, Hirotaka Ikeda, Akiyoshi Iwase, Takashi Fukuba, Hidekazu Hattori, Kazuhiro Murayama and 4 more

Abstract readReview
In one paragraph

Review in Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. New developments in the imaging of lung cancer.Breathe (Sheffield, England) · 2024
    Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yumi TanakaDepartment of Radiology, Fujita Health University School of Medicine.
Yoshiharu OhnoDepartment of Radiology, Fujita Health University School of Medicine.
Satomu HanamatsuDepartment of Radiology, Fujita Health University School of Medicine.
Yuki ObamaDepartment of Radiology, Fujita Health University School of Medicine.
Takahiro UedaDepartment of Radiology, Fujita Health University School of Medicine.
Hirotaka IkedaDepartment of Radiology, Fujita Health University School of Medicine.
Akiyoshi IwaseDepartment of Radiology, Fujita Health University Hospital.
Takashi FukubaDepartment of Radiology, Fujita Health University Hospital.
Hidekazu HattoriDepartment of Radiology, Fujita Health University School of Medicine.
Kazuhiro MurayamaJoint Research Laboratory of Advanced Medical Imaging, Fujita Health University School of Medicine.
Takeshi YoshikawaDepartment of Diagnostic Radiology, Hyogo Cancer Center.
Daisuke TakenakaDepartment of Diagnostic Radiology, Hyogo Cancer Center.
Hisanobu KoyamaDepartment of Radiology, Osaka Police Hospital.
Hiroshi ToyamaDepartment of Radiology, Fujita Health University School of Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since thoracic MR imaging was first used in a clinical setting, it has been suggested that MR imaging has limited clinical utility for thoracic diseases, especially lung diseases, in comparison with x-ray CT and positron emission tomography (PET)/CT. However, in many countries and states and for specific indications, MR imaging has recently become practicable. In addition, recently developed pulmonary MR imaging with ultra-short TE (UTE) and zero TE (ZTE) has enhanced the utility of MR imaging for thoracic diseases in routine clinical practice. Furthermore, MR imaging has been introduced as being capable of assessing pulmonary function. It should be borne in mind, however, that these applications have so far been academically and clinically used only for healthy volunteers, but not for patients with various pulmonary diseases in Japan or other countries. In 2020, the Fleischner Society published a new report, which provides consensus expert opinions regarding appropriate clinical indications of pulmonary MR imaging for not only oncologic but also pulmonary diseases. This review article presents a brief history of MR imaging for thoracic diseases regarding its technical aspects and major clinical indications in Japan 1) in terms of what is currently available, 2) promising but requiring further validation or evaluation, and 3) developments warranting research investigations in preclinical or patient studies. State-of-the-art MR imaging can non-invasively visualize lung structural and functional abnormalities without ionizing radiation and thus provide an alternative to CT. MR imaging is considered as a tool for providing unique information. Moreover, prospective, randomized, and multi-center trials should be conducted to directly compare MR imaging with conventional methods to determine whether the former has equal or superior clinical relevance. The results of these trials together with continued improvements are expected to update or modify recommendations for the use of MRI in near future.

Indexed as

Lung NeoplasmsThoracic DiseasesHumansMagnetic Resonance ImagingPositron-Emission TomographyProspective StudiesTomography, X-Ray Computedlungmagnetic resonance imagingmediastinumthorax

Identifiers

PMID33952785
PMCPMC9199970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.